Ionetix Corp / DE /

Ionetix Corp is a Delaware-incorporated company operating in the nuclear medicine and radiopharmaceuticals sector, focused on the production of fluorine-18 radioisotopes used in positron emission tomography imaging. The company filed an amended current report on Form 8-K/A with the Securities and Exchange Commission on May 20, 2026, under accession number 0001213900-26-059661, supplementing a previously disclosed material event. Ionetix reached the public markets through a SPAC transaction in the healthcare and life sciences space. Investors and analysts tracking SPAC-sourced healthcare issuers can find comprehensive filing histories, deal timelines, and sponsor data for Ionetix Corp and hundreds of comparable companies by signing up for full access at SpacDesk.